FIG. 5.

Life table analysis of islet allograft survival in NOD mice treated with IL-2. Groups of 6- to 8-week-old chemically diabetic NOD mice were treated with a C3H/He DST on day −7 and anti-CD154 mAb (0.5 mg/dose) on days −7, −4, 0, and +4 relative to transplantation with C3H/He islets on day 0. One group of mice also received 0.8 μg recombinant murine IL-2 (R&D systems, Minneapolis, MN) intraperitoneally on days −7, −6, −5, −4, and −3 relative to islet transplantation on day 0. *P < 0.05 vs. NOD.